ACADIA Pharmaceuticals (ACAD) Given a $50.00 Price Target by JPMorgan Chase & Co. Analysts

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been assigned a $50.00 price target by research analysts at JPMorgan Chase & Co. in a report issued on Sunday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 199.22% from the company’s previous close.

ACAD has been the topic of a number of other research reports. BidaskClub cut ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 11th. Zacks Investment Research cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 9th. ValuEngine cut ACADIA Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, March 23rd. Finally, HC Wainwright restated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, May 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $47.45.

ACADIA Pharmaceuticals traded up $1.44, reaching $16.71, during midday trading on Friday, according to Marketbeat. 4,271,700 shares of the company were exchanged, compared to its average volume of 2,838,510. ACADIA Pharmaceuticals has a one year low of $14.51 and a one year high of $41.20. The stock has a market cap of $1.91 billion, a P/E ratio of -7.08 and a beta of 3.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Friday, May 4th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.12. ACADIA Pharmaceuticals had a negative return on equity of 71.47% and a negative net margin of 161.44%. The firm had revenue of $48.90 million for the quarter, compared to analysts’ expectations of $47.06 million. During the same quarter last year, the business earned ($0.72) earnings per share. The company’s revenue was up 219.6% compared to the same quarter last year. equities analysts expect that ACADIA Pharmaceuticals will post -1.71 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Stevens Capital Management LP lifted its holdings in shares of ACADIA Pharmaceuticals by 4.8% during the 1st quarter. Stevens Capital Management LP now owns 61,319 shares of the biopharmaceutical company’s stock valued at $1,378,000 after purchasing an additional 2,802 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of ACADIA Pharmaceuticals by 1.7% during the 1st quarter. New York State Common Retirement Fund now owns 211,300 shares of the biopharmaceutical company’s stock valued at $4,748,000 after purchasing an additional 3,500 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of ACADIA Pharmaceuticals by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 456,482 shares of the biopharmaceutical company’s stock valued at $13,746,000 after purchasing an additional 3,786 shares in the last quarter. Point72 Asia Hong Kong Ltd lifted its holdings in shares of ACADIA Pharmaceuticals by 822.9% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 4,439 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 3,958 shares in the last quarter. Finally, Xact Kapitalforvaltning AB lifted its holdings in shares of ACADIA Pharmaceuticals by 37.7% during the 1st quarter. Xact Kapitalforvaltning AB now owns 15,332 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 4,200 shares in the last quarter. Institutional investors and hedge funds own 97.19% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply